NeuroBo Pharmaceuticals Inc. (NRBO): Technicals Say You should Hold

0
11
KOSK
KOSK

NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) saw an upside of 42.40% to close Tuesday at $20.79 after adding $6.19 on the day. The 5-day average trading volume is 3,727,040 shares of the company’s common stock. It has gained $29.88 in the past week and touched a new high 2 times within the past 5 days. An average of 1,552,571 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 622,939.

NRBO’s 1-month performance is 81.79% or $9.35 on its low of $7.39 reached on 08/31/22. The company’s shares have touched a 52-week low of $7.39 and high of $123.90, with the stock’s rally to the 52-week high happening on 09/13/22. YTD, NRBO has lost -43.20% or -$15.81 and has reached a new high 3 times. However, the current price is down -83.22% from the 52-week high price.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Valuation Metrics

NRBO stock has a beta of 0.24. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.09.

NeuroBo Pharmaceuticals Inc.’s quick ratio for the period ended September 29 was 8.10, with the current ratio over the same period at 8.10. The firm’s gross profit as reported stood at $14000.0 against revenue of $15.3 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -18.79% to -$3.3 million, while revenue of -$2.88 million was 12.73% off the previous quarter. Analysts expected NRBO to announce -$5.4 per share in earnings in its latest quarter, but it posted -$4.8, representing a 11.10% surprise. EBITDA for the quarter stood at more than -$3.21 million. Shareholders hold equity totaling $0.89 million.

Let’s look briefly at NeuroBo Pharmaceuticals Inc. (NRBO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 20 September was 56.85% to suggest the stock is trending Neutral, with historical volatility in this time period at 648.45%.

The stock’s 5-day moving average is $19.00, reflecting a -30.47% or -$9.11 change from its current price. NRBO is currently trading +79.53% above its 20-day SMA, +19.03% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +18.62% and SMA200 by-53.49%.

Stochastic %K and %D was 18.38% and 20.41% and the average true range (ATR) pointed at 8.60. The RSI (14) points at 56.64%, while the 14-day stochastic is at 23.73% with the period’s ATR at 6.76. The stock’s 9-day MACD Oscillator is pointing at 0.13 and 3.12 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO), H.C. Wainwright launched coverage with a Buy rating.

LEAVE A REPLY

Please enter your comment!
Please enter your name here